JP2021522793A5 - - Google Patents
Info
- Publication number
- JP2021522793A5 JP2021522793A5 JP2020561726A JP2020561726A JP2021522793A5 JP 2021522793 A5 JP2021522793 A5 JP 2021522793A5 JP 2020561726 A JP2020561726 A JP 2020561726A JP 2020561726 A JP2020561726 A JP 2020561726A JP 2021522793 A5 JP2021522793 A5 JP 2021522793A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- acid sequence
- item
- seq
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666547P | 2018-05-03 | 2018-05-03 | |
| US62/666,547 | 2018-05-03 | ||
| US201862779998P | 2018-12-14 | 2018-12-14 | |
| US62/779,998 | 2018-12-14 | ||
| PCT/US2019/030469 WO2019213442A1 (en) | 2018-05-03 | 2019-05-02 | MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522793A JP2021522793A (ja) | 2021-09-02 |
| JP2021522793A5 true JP2021522793A5 (https=) | 2022-05-13 |
| JPWO2019213442A5 JPWO2019213442A5 (https=) | 2022-05-13 |
Family
ID=68386158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561726A Pending JP2021522793A (ja) | 2018-05-03 | 2019-05-02 | ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12103959B2 (https=) |
| EP (1) | EP3788066A4 (https=) |
| JP (1) | JP2021522793A (https=) |
| AU (1) | AU2019262139A1 (https=) |
| CA (1) | CA3099527A1 (https=) |
| WO (1) | WO2019213442A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4073101A4 (en) * | 2019-12-10 | 2024-01-10 | Acceleron Pharma Inc. | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHOD FOR TREATING PULMONARY HYPERTENSION |
| KR20230117348A (ko) * | 2020-11-04 | 2023-08-08 | 에이치큐 한 | Tgf-베타 계열의 다중 리간드를 저해할 수 있는 신규한 이작용성 다중특이적 길항제 및 이의 용도 |
| US20240277807A1 (en) * | 2021-06-11 | 2024-08-22 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| CN107849114B (zh) * | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| US10227392B2 (en) * | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| AU2017293778B2 (en) * | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| US11440949B2 (en) * | 2016-10-05 | 2022-09-13 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| CN206301918U (zh) * | 2016-12-23 | 2017-07-04 | 深圳国人通信股份有限公司 | 一种介质移相器 |
| CA3099325A1 (en) * | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | Novel binders of tgf.beta.-superfamily ligands and uses thereof |
| EP3807308A4 (en) * | 2018-06-15 | 2022-03-16 | Acceleron Pharma Inc. | BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
-
2019
- 2019-05-02 WO PCT/US2019/030469 patent/WO2019213442A1/en not_active Ceased
- 2019-05-02 US US17/052,785 patent/US12103959B2/en active Active
- 2019-05-02 CA CA3099527A patent/CA3099527A1/en active Pending
- 2019-05-02 EP EP19796599.9A patent/EP3788066A4/en active Pending
- 2019-05-02 JP JP2020561726A patent/JP2021522793A/ja active Pending
- 2019-05-02 AU AU2019262139A patent/AU2019262139A1/en not_active Abandoned
-
2024
- 2024-08-21 US US18/811,531 patent/US20250109179A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3218411B1 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| JP2021522795A5 (https=) | ||
| JP7303629B2 (ja) | 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物 | |
| CN104245735B (zh) | Cx3cr1结合多肽 | |
| JP6809789B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| US20230348565A1 (en) | Methods of using activin receptor type ii variants | |
| JP2021175391A5 (https=) | ||
| EA032727B1 (ru) | Мутантный резистентный к протеолизу полипептид fgf21 и его применение | |
| JP2021522793A5 (https=) | ||
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| JP7793774B2 (ja) | メソテリン結合タンパク質及びその使用 | |
| WO2019246288A1 (en) | Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries | |
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2021513366A (ja) | 抗ｐｄ−１／抗ｈｅｒ２天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法 | |
| JP2020500511A5 (https=) | ||
| CN112839681A (zh) | 寡聚体延伸的胰岛素-Fc缀合物及其医学用途 | |
| JPWO2019213446A5 (https=) | ||
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| JPWO2019213442A5 (https=) | ||
| JP2025527160A (ja) | 多重特異性抗体およびその使用 | |
| JPWO2021078774A5 (https=) | ||
| CN117295758A (zh) | 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白 | |
| JP7829127B2 (ja) | 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質 | |
| JP2025524899A (ja) | メソテリン結合タンパク質及びその使用 | |
| TW202342551A (zh) | 包含抗原結合結構域及細胞因數三聚體結構域的融合蛋白 |